The supportive in vitro results in both hESCs and CCLs were followed by an in vivo experiment to assess the impact of blebbistatin on cancer growth in both TP53‐deficient (LS411N) and proficient (HCT116 and LoVo) cells. This evidence concerns the gene TP53 and cancer.